Market Overview:
The global recombinant antibody market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, rising demand for monoclonal antibodies, and technological advancements in the field of recombinant antibody production. Based on type, the global recombinant antibody market is segmented into chimeric antibodies, humanized antibodies, full human antibodies, single chain antibodies, and bispecific antibodies. Chimeric Antibodies are currently dominating this market with a share of more than 50%. However Bispecific Antibodies are projected to witness highest growth rate during the forecast period owing to their ability to target two different antigens simultaneously. Bispecific Antibodies have found application in various therapeutic areas such as cancer immunotherapy and autoimmune diseases. On basis of application hospitals account for majority share in terms revenue generated however scientific research institutes are anticipated witness highest CAGR over next decade due ongoing researches for novel therapies & cures .
Product Definition:
Recombinant antibodies are made by splicing together DNA fragments that encode the heavy and light chains of an antibody. This recombinant DNA is then introduced into a bacterial or yeast cell, which produces large quantities of the antibody. Recombinant antibodies can be used to treat cancer, autoimmune diseases, and other conditions.
Chimeric Antibody:
A chimeric antibody is a hybrid protein, which consists of portions of two antibodies linked by an amino acid link. It has been designed to have the ability to bind its target antigen with greater affinity than either parent antibody alone. The first half of the molecule is derived from one parent antibody and the second half is derived from another.
Humanized Antibody:
Humanized antibody is a type of recombinant antibody, which is the protein made by combining the antigen binding portion of an animal's antibodies with human immunoglobulin. The most commonly used species for producing humanized antibodies are mice and rats. Humanization can be done to any type of monoclonal antibody by grafting a small fragment of complementary heavy chain or light chain from an immune donor into the patient's own body.
Application Insights:
The hospital application segment led the global market in 2017. The segment is expected to witness significant growth over the forecast period owing to increasing prevalence of chronic diseases, especially diabetes and rising number of surgeries. Increasing healthcare spending and government initiatives such as ¢â‚¬Å“Make In India¢â‚¬ are likely to propel the growth of this segment further.
Recombinant antibodies have numerous applications in research including drug discovery & development, protein engineering for improved therapeutic efficacy & efficiency, diagnosis of disease states & infections by detecting antibody biomarkers thereby aiding medical professionals in making accurate diagnoses.
Regional Analysis:
North America dominated the global market in 2017. The presence of a large number of biotechnology and pharmaceutical companies, which are engaged in R&D for the development of therapeutic proteins derived from antibodies is one major factor responsible for its continued dominance over the forecast period. In addition, increasing government funding to support research activities pertaining to rAAVs is also expected to contribute toward regional growth during the same period.
Asia Pacific region is anticipated to witness lucrative growth over the forecast period owing to factors such as rising disposable income and healthcare expenditure coupled with growing investments by governments in emerging economies including China & India for developing advanced therapeutics using recombinant protein technology. Furthermore, increasing focus on drug discovery & development by leading players operating across various sectors including biopharmaceuticals and medical devices may also drive this regional market during future years.
Growth Factors:
- Increasing prevalence of chronic diseases: The global prevalence of chronic diseases is increasing at an alarming rate. This is primarily because of the changing lifestyles and dietary habits of people across the world. According to a study by the World Health Organization (WHO), non-communicable diseases such as cancer, cardiovascular disease, diabetes, and respiratory disorders are responsible for over 60% of all deaths worldwide. This is expected to drive the demand for recombinant antibodies in the coming years.
- Growing demand for personalized medicine: The field of personalized medicine is growing rapidly due to the increasing need for customized treatments specific to an individual’s genetic makeup or lifestyle factors. Recombinant antibodies are increasingly being used in personalized medicine due to their high specificity and accuracy levels. This is expected to boost the growth prospects of this market in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Recombinant Antibody Market Research Report
By Type
Chimeric Antibody, Humanized Antibody, Full Human Antibody, Single Chain Antibody, Bispecific Antibody
By Application
Hospital, Scientific Research, Others
By Companies
Abnova, Medix Biochemica, GE Healthcare, SinoBiological, Bioventix
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
235
Number of Tables & Figures
165
Customization Available
Yes, the report can be customized as per your need.
Global Recombinant Antibody Market Report Segments:
The global Recombinant Antibody market is segmented on the basis of:
Types
Chimeric Antibody, Humanized Antibody, Full Human Antibody, Single Chain Antibody, Bispecific Antibody
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Scientific Research, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Abnova
- Medix Biochemica
- GE Healthcare
- SinoBiological
- Bioventix
Highlights of The Recombinant Antibody Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chimeric Antibody
- Humanized Antibody
- Full Human Antibody
- Single Chain Antibody
- Bispecific Antibody
- By Application:
- Hospital
- Scientific Research
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Recombinant Antibody Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Recombinant antibody is a type of antibody that has been made in a laboratory. This means that the antibodies have been created by combining pieces of different proteins together.
Some of the key players operating in the recombinant antibody market are Abnova, Medix Biochemica, GE Healthcare, SinoBiological, Bioventix.
The recombinant antibody market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Recombinant Antibody Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Recombinant Antibody Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Recombinant Antibody Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Recombinant Antibody Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Recombinant Antibody Market Size & Forecast, 2018-2028
4.5.1 Recombinant Antibody Market Size and Y-o-Y Growth
4.5.2 Recombinant Antibody Market Absolute $ Opportunity
Chapter 5 Global Recombinant Antibody Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Recombinant Antibody Market Size Forecast by Type
5.2.1 Chimeric Antibody
5.2.2 Humanized Antibody
5.2.3 Full Human Antibody
5.2.4 Single Chain Antibody
5.2.5 Bispecific Antibody
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Recombinant Antibody Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Recombinant Antibody Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Scientific Research
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Recombinant Antibody Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Recombinant Antibody Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Recombinant Antibody Analysis and Forecast
9.1 Introduction
9.2 North America Recombinant Antibody Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Recombinant Antibody Market Size Forecast by Type
9.6.1 Chimeric Antibody
9.6.2 Humanized Antibody
9.6.3 Full Human Antibody
9.6.4 Single Chain Antibody
9.6.5 Bispecific Antibody
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Recombinant Antibody Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Scientific Research
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Recombinant Antibody Analysis and Forecast
10.1 Introduction
10.2 Europe Recombinant Antibody Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Recombinant Antibody Market Size Forecast by Type
10.6.1 Chimeric Antibody
10.6.2 Humanized Antibody
10.6.3 Full Human Antibody
10.6.4 Single Chain Antibody
10.6.5 Bispecific Antibody
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Recombinant Antibody Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Scientific Research
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Recombinant Antibody Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Recombinant Antibody Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Recombinant Antibody Market Size Forecast by Type
11.6.1 Chimeric Antibody
11.6.2 Humanized Antibody
11.6.3 Full Human Antibody
11.6.4 Single Chain Antibody
11.6.5 Bispecific Antibody
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Recombinant Antibody Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Scientific Research
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Recombinant Antibody Analysis and Forecast
12.1 Introduction
12.2 Latin America Recombinant Antibody Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Recombinant Antibody Market Size Forecast by Type
12.6.1 Chimeric Antibody
12.6.2 Humanized Antibody
12.6.3 Full Human Antibody
12.6.4 Single Chain Antibody
12.6.5 Bispecific Antibody
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Recombinant Antibody Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Scientific Research
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Recombinant Antibody Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Recombinant Antibody Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Recombinant Antibody Market Size Forecast by Type
13.6.1 Chimeric Antibody
13.6.2 Humanized Antibody
13.6.3 Full Human Antibody
13.6.4 Single Chain Antibody
13.6.5 Bispecific Antibody
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Recombinant Antibody Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Scientific Research
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Recombinant Antibody Market: Competitive Dashboard
14.2 Global Recombinant Antibody Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Abnova
14.3.2 Medix Biochemica
14.3.3 GE Healthcare
14.3.4 SinoBiological
14.3.5 Bioventix
